NICE recommends digital tech for ADHD diagnosis in children and young people

Betsy Goodfellow | July 16, 2024 | News story | Medical Communications ADHD, Diagnostics, NICE 

The National Institute for Health and Care Excellence (NICE) has announced that its diagnostics advisory committee has recommended the QbTest alongside standard clinical assessment to aid in the diagnosis of ADHD in children and young people between the ages of six and 17.

The newly recommended QbTest is a computer-based test which tracks a participant’s movements, while measuring three symptoms of ADHD: inattention, impulsivity and hyperactivity.

Results from the AQUA clinical trial demonstrated that using the QbTest along with a standard clinical assessment for ADHD led to a diagnostic decision being made for a greater proportion of people within six months of their first assessment appointment, compared to assessment not using the QbTest. The test was also able to rule out ADHD in more cases.

Advertisement

Mark Chapman, director of NICE’s HealthTech, commented: “Children and young people with ADHD deserve to receive a diagnosis in a timely manner. We heard from our patient experts there are challenges with current pathways. We’re committed to ensuring we get the best care to people fast while providing value for money to the taxpayer. This technology has the potential to generate tangible benefits to the lives of those waiting for an ADHD diagnosis. Evidence presented to our committee showed the QbTest could increase the number of children and young people who get a diagnostic decision within 6 months of starting assessment.”

Betsy Goodfellow

Related Content

NICE recommends allergy immunotherapy tablets for younger children

NICE has recommended two sublingual immunotherapy tablets for children with moderate to severe allergic rhinitis …

Functional lung imaging offers new possibilities for respiratory care

Advances in computed tomography (CT) technology are helping to reshape the diagnosis and management of …

NICE backs atogepant for acute migraine treatment

NICE has issued Final Draft Guidance recommending AbbVie’s AQUIPTA (atogepant) as an option for the …

The Gateway to Local Adoption Series

Latest content